Eton Pharmaceuticals, Inc.

ETON

US29772L1089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.21 ^USD	-2.13%		+2.23%	-26.71%

Apr. 17	Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	CI
Apr. 15	Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	CI

ETON PHARMACEUTICALS, INC. : Other Events (form 8-K)

August 15, 2022 at 06:31 am EDT

Item 8.01 Other Events.

Eton was notified of a decision in the Paragraph IV litigation regarding cysteine hydrochloride injection. The court ruled to uphold Exela Pharma Science's patents. Eton strongly disagrees with the decision and expects Dr. Reddy's Laboratories to appeal the ruling. Eton sold the product to Dr. Reddy's Laboratories in June 2022, and Dr. Reddy's Laboratories is responsible for all legal activities. Eton could still receive a milestone payment if Dr. Reddy's Laboratories prevails on appeal and launches the product.

Latest news about Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	Apr. 16	CI
Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	Apr. 14	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Sector Update: Health Care	Mar. 22	MT
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	Mar. 22	CI
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	Mar. 22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	Mar. 22	MT
Transcript : Eton Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q4 Revenue $7.3M, vs. Street Est of $7.66M	Mar. 14	MT
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	Feb. 21	MT
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	Feb. 21	CI
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US	Feb. 02	MT
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules	Feb. 02	CI
Transcript : Eton Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q3 Revenue $7M, vs. Street Est of $6.3M	Nov. 09	MT
Eton Pharmaceuticals to Acquire Nitisinone Drug From Oakrum Pharma	23-10-04	MT
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone	23-10-04	CI
Top Premarket Gainers	23-08-11	MT
HC Wainwright Adjusts Eton Pharmaceuticals Price Target to $10 From $9, Maintains Buy Rating	23-08-11	MT
Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023	23-08-10	CI
Transcript : Eton Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q2 Revenue $12M, vs. Street Est of $6.5M	23-08-10	MT

Chart Eton Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.28 USD

Average target price

10 USD

Spread / Average Target

+204.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ETON PHARMACEUTICALS, INC.	-26.71%	84.26M
MERCK KGAA	+5.73%	71.48B
KYOWA KIRIN CO. LTD.	+11.94%	9.18B
SK BIOPHARMACEUTICALS CO., LTD.	-15.34%	4.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+34.54%	3.98B
YUHAN CORPORATION	+5.09%	3.97B
INDIVIOR PLC	+27.76%	2.56B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.33%	2.29B
BETTA PHARMACEUTICALS CO., LTD.	-24.15%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+6.23%	1.92B

Specialty & Advanced Pharmaceuticals